Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
Completed
Cephalon
Phase 3
2008-07-01
This study is an open-label study where all subjects will receive active drug, reslizumab.
Subjects are able to enter this trial only through completion of study Res-05-0002
(NCT00538434).
The goal of the study is to show longer term safety and efficacy in pediatric subjects who
have eosinophilic esophagitis.
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
Completed
Ception Therapeutics
Phase 3
2008-07-01
This study is an open-label study where all subjects will receive active drug, reslizumab.
Subjects are able to enter this trial only through completion of study Res-05-0002
(NCT00538434).
The goal of the study is to show longer term safety and efficacy in pediatric subjects who
have eosinophilic esophagitis.
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
2010-04-01
Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the
development of severe adverse reactions that are correlated with the number of circulating
microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied
by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of
eosinophil activation. This randomized, placebo-controlled, double-blind pilot study
(conducted at the NIH Clinical Center) will assess whether and to what extent the
administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against
IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3
times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with
Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity
of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on
microfilarial clearance.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
